What human clinical trials have specifically measured serum creatinine, BUN, or eGFR before and after ivermectin treatment at standard doses?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Human trials of ivermectin commonly included routine “renal function” testing, and several published COVID-19 and infectious-disease trials explicitly measured serum creatinine and reported it in analyses, but few trials present detailed before-and-after tables of serum creatinine, BUN, or calculated eGFR at standard human dosing in ways that allow straightforward pooled conclusions [1] [2] [3]. Clinical trial registries and lab-reporting standards show that serum creatinine and eGFR are standard safety endpoints, yet the accessible published reports vary in how completely they report pre- and post-treatment renal markers and BUN specifically [4] [5] [6].
1. What the question actually asks and why it matters
The user asks for human clinical trials that specifically measured serum creatinine, BUN, or eGFR before and after ivermectin at standard doses — a request that requires locating trials with explicit, time‑matched renal biochemistry reporting rather than trials that merely list “renal function” among many labs; such data are essential to assess nephrotoxicity risk and to inform dose adjustments but are not always fully published in trial reports [1] [5] [6].
2. Trials that explicitly measured serum creatinine in published reports
Several randomized or controlled clinical trials of ivermectin measured serum creatinine as part of safety labs: the pilot double‑blind randomized trial published in eClinicalMedicine collected blood for “renal function” on enrollment and days 7 and 14 and thus measured renal markers during follow‑up [1], and an Egyptian randomized controlled study of ivermectin in COVID‑19 listed creatinine among variables related to mortality in its regression model, indicating serum creatinine was measured and analyzed [2]. The I‑TECH randomized clinical trial also referenced creatinine in its laboratory methods and data handling, showing serum creatinine was recorded during the study [3]. Each of these sources therefore documents human trials that measured serum creatinine before and after ivermectin administration [1] [2] [3].
3. Trials that reported BUN or eGFR specifically — sparse direct reporting
Among the accessible reporting in the set provided, explicit pre/post BUN values are rarely published in the clinical trial manuscripts cited; most papers refer more generally to “renal function” or list creatinine in regression models without providing full BUN tables in the main text [1] [2]. eGFR is conceptually derived from serum creatinine and is routinely recommended for trial reporting per lab standards [5] [6], and at least one clinical diagram from a scabies study shows serum creatinine evolution with an eGFR statement (research diagram), indicating eGFR was calculated in that study cohort though the primary report is not fully available in the provided material [7].
4. Registries, guidance and missing data — why there is ambiguity
Clinical trial registries (e.g., NCT entries) list ivermectin trials and often include laboratory safety assessments, but many registry entries lack posted results, and published papers sometimes omit granular lab tables even when they collected serial creatinine/BUN data [4] [1]. Standard data models and reporting guidance (CDISC, CKD‑EPI for eGFR) make serum creatinine and calculated eGFR standard safety endpoints, but the degree to which BUN specifically is reported varies by trial and by journal [5] [6].
5. Animal data and mechanistic context — human relevance and limits
Animal toxicology studies demonstrate ivermectin can alter serum creatinine and BUN in rodents at certain doses and durations, supporting a biological plausibility for renal effects under some conditions, but these are animal findings and do not substitute for human pre/post lab reporting [8] [9]. The reviewed human trials measured creatinine in safety labs, yet accessible publications in this reporting set rarely present comprehensive before‑and‑after BUN/eGFR tables, leaving a gap between data collected and data fully reported [1] [2] [3].
6. Bottom line and research gaps
Published human trials cited here (including the eClinicalMedicine pilot trial, the Egyptian randomized controlled COVID‑19 study, and the I‑TECH RCT) did measure serum creatinine during treatment and thus meet part of the user’s criterion, but BUN and formal eGFR time‑series are infrequently published in accessible tables; registry entries exist but often lack posted results, so confirming full pre/post BUN and eGFR across standard‑dose human trials requires either access to supplementary data or contacting study authors [1] [2] [3] [4] [5]. Animal studies show renal marker changes, highlighting why comprehensive human renal reporting matters, but they cannot answer the human pre/post question [8].